← Russell 3000 cross-section

OSUR ORASURE TECHNOLOGIES INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-07, not restated
Healthcare

Scale

Market cap
$257m
Revenue TTM
$112m
Net income TTM
$-49m
Free cash flow
$-48m
Composite score
42.1
Sector rank
#2756

Valuation

P / E
EV / EBITDA
EV / sales
0.9
FCF yield
-18.71%
Earnings yield vs 10-yr
-23.84pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-43.7%
EBITDA margin
-39.5%
ROE
-15.5%
ROIC
-34.4%
Revenue growth
-18.9%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Initial sales of this product for research use only are occurring primarily through distributors and collaborations in the liquid biopsy and sexually transmitted disease markets. Risk Assessment Testing During the third quarter of 2024, the Company announced the discontinuance of sales of its risk assessment product line, which was completed in the second quarter of 2025. Product and Services Revenues Consolidated net revenues decreased 2% to $30.6 million for the three months ended June 30, 2026 from $31.2 million for the three months ended June 30, 2025. …ORASURE TECHNOLOGIES INC, 10-Q, period ended 2026-06-30, filed 2026-08-07

Read the full passage →